Rhythm Pharmaceuticals Shares Rise on Strong Q1 Earnings and FDA Approval
Rhythm Pharmaceuticals (RYTM) saw its stock rise nearly 8% after reporting better-than-expected first-quarter revenue driven by its FDA-approved drug Imcivree. Revenue nearly doubled to $60.1 million compared to $32.7 million in the same period last year, although the company reported a wider net loss due to increased SG&A expenses.
Tickers: $RYTM
Topics: biotech earnings FDA approval revenue growth